This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jul;5(7):e336-e337.

doi: 10.1016/S2352-3018(18)30099-7. Epub 2018 Jun 18.

What did we learn from the bictegravir switch studies?

Marianne Harris¹

Affiliations

PMID: 29925488
DOI: 10.1016/S2352-3018(18)30099-7

Comment

What did we learn from the bictegravir switch studies?

Marianne Harris. Lancet HIV. 2018 Jul.

. 2018 Jul;5(7):e336-e337.

doi: 10.1016/S2352-3018(18)30099-7. Epub 2018 Jun 18.

Author

Marianne Harris¹

Affiliation

¹ British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. Electronic address: mharris@cfenet.ubc.ca.

PMID: 29925488
DOI: 10.1016/S2352-3018(18)30099-7

No abstract available

PubMed Disclaimer

Comment in

Antiretroviral switch studies do matter.
Daar ES, Ruane P, DeJesus E, Stellbrink HJ, Molina JM. Daar ES, et al. Lancet HIV. 2018 Oct;5(10):e546. doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8. Lancet HIV. 2018. PMID: 30319119 No abstract available.

Comment on

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E. Molina JM, et al. Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925489 Clinical Trial.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Daar ES, et al. Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925490 Clinical Trial.

Similar articles

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Daar ES, et al. Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925490 Clinical Trial.
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Sax PE, et al. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15. Lancet HIV. 2017. PMID: 28219610 Clinical Trial.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED. Deeks ED. Drugs. 2018 Nov;78(17):1817-1828. doi: 10.1007/s40265-018-1010-7. Drugs. 2018. PMID: 30460547 Free PMC article. Review.
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Zeuli J, Rizza S, Bhatia R, Temesgen Z. Zeuli J, et al. Drugs Today (Barc). 2019 Nov;55(11):669-682. doi: 10.1358/dot.2019.55.11.3068796. Drugs Today (Barc). 2019. PMID: 31840682 Review.

See all similar articles

Cited by

Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World.
de Gea-Grela A, Micán R, de Miguel R, Serrano L, Marcelo C, Montes ML, Ramos-Ruperto L, Busca C, Arcos-Rueda MDM, Montejano R, Arribas JR, Gonzalez-García J, Bernardino JI, Martín-Carbonero L. de Gea-Grela A, et al. Open Forum Infect Dis. 2025 Feb 27;12(3):ofaf087. doi: 10.1093/ofid/ofaf087. eCollection 2025 Mar. Open Forum Infect Dis. 2025. PMID: 40059977 Free PMC article. Clinical Trial.
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management.
Ellis RJ, Marquine MJ, Kaul M, Fields JA, Schlachetzki JCM. Ellis RJ, et al. Nat Rev Neurol. 2023 Nov;19(11):668-687. doi: 10.1038/s41582-023-00879-y. Epub 2023 Oct 10. Nat Rev Neurol. 2023. PMID: 37816937 Free PMC article. Review.
CNS Neurotoxicity of Antiretrovirals.
Lanman T, Letendre S, Ma Q, Bang A, Ellis R. Lanman T, et al. J Neuroimmune Pharmacol. 2021 Mar;16(1):130-143. doi: 10.1007/s11481-019-09886-7. Epub 2019 Dec 10. J Neuroimmune Pharmacol. 2021. PMID: 31823251 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations